Fidanacogene Elaparvovec for hemophilia a

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 4 Mar 2019: Trial registered, NCT03861273
  2. 29 Jul 2019: Trial started, NCT03861273

The trials

NCT03861273: A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

State
Under way
Phase
Phase 3
People
51 taking part
Started
29 Jul 2019
Primary completion
16 Nov 2022
Arms
PF-06838435/ fidanacogene elaparvovec
Results
Posted on the registry
Papers
doi:10.1007/s40262-025-01535-y, doi:10.1056/nejmoa2302982
  1. 4 Mar 2019: Trial registered
  2. 29 Jul 2019: Trial started
  3. 27 Mar 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as PF-06838435 (formerly SPK-9001), PF-06838435/ fidanacogene elaparvovec.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.